Tregalizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tregalizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target CD4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 ☒N☑Y (what is this?)  (verify)

Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]

References[edit]

  1. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4). 
  2. ^ Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B, Jonuleit H, Kubach J, Dingermann T, Radeke HH, Osterroth F, Uherek C, Czeloth N, Schüttrumpf J (April 2015). "A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway". Immunol Cell Biol. 93 (4): 396–405. PMC 4407014Freely accessible. 
  3. ^ König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J (Jan 2016). "Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells". Frontiers in Immunology. 7. PMC 4724712Freely accessible.